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California Assemblyman Paul Koretz (D-West Hollywood) intro-
duced a bill to raise the legal smoking age in the state from 18
to 21. The objective of this research is to estimate the public
health and economic impacts of raising the California legal
smoking age to 21. METHODS: To estimate the health and eco-
nomic impacts, we created a dynamic computer simulation
model. The model simulates the California population as they
age and change their smoking behavior over time. Secondary
data for model parameters were obtained from publicly avail-
able sources. Population health impacts were estimated in terms
of change in smoking prevalence and the change in cumulative
quality-adjusted life-years (QALYs) to the California population
over a 50-year period. Economic impacts were measured in mon-
etary terms for medical cost savings, cost of law enforcement and
cost of checking identiﬁcation. RESULTS: Smoking prevalence
among teens (age 14–17) will drop to 2.4% from current levels
of 13.3%, an 82% reduction. There will be savings of 24 billion
and 1.47 million QALYs will be gained over a period of 50 years
compared to status quo. CONCLUSIONS: This research should
prove useful to California’s policy makers as they contemplate
legislation to raise the state’s legal smoking age.
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THE IMPACT OF LOW MOLECULAR WEIGHT HEPARIN
(LMWH) ENOXAPARIN USAGE ON OUTCOMES OF
TREATMENT MANAGEMENT OF PATIENTS WITH ACUTE
CORONARY SYNDROMES (ACS) IN RUSSIA
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OBJECTIVES: Creation of Russian Registry of patients in ACS.
Pharmacoeconomic assessment of costs and consequences of
non-ST segment evaluation ACS (NSTE ACS) by traditional anti-
coagulants and LMWH enoxaparin usage. METHODS: Registry
1 was produced in July 2001 by inclusion of 50 adult hospital
patients in ACS from 59 clinics of Russian cities. A total of 1394
patients were with NSTE ACS, 64% of them received unfrac-
tionated heparin (UFH) and 7.4%—LMWH. Registry 2 was
done in 2003 according the same criteria. A total of 1185
patients from 32 clinics were enrolled. 659 of them were with
NSTE ACS, 19% were treated by UFH, 60%—by enoxaparin.
Pharmacoeconomic analysis “cost—effectiveness” was succeed
as: k = C2 - C1 / E2 - E1. Ñ2 and Ñ1—average value of Cost
per hospital patient in Registry 2 and 1 accordingly (including
costs of treatment and resource utilization). Å2 and Å1—prob-
ability of successful outcomes of the disease in Registry 2 and 1
as well, k—cost per 1% of grow of effectiveness of the treat-
ment. RESULTS: There weren’t statistical discrepancy between
clinical characteristics and duration of hospitalization of patients
into the Registry 1 and 2. A share of more effective treated
patients has been increased in Registry 2 versus Registry 1. Prob-
ability of mortality decreased by 2.3%, reinfarct—by 6.8%,
refractory angina—by 6.3% (g < 0.001). Probability of success-
ful outcomes (E2 - E1) increased by 14.9%. Ñ2 = USD 160.68;
C1 = USD 100.64; E2 = 75.9%; E1 = 61%, K = USD 4.03/ %.
CONCLUSION: Probably the rise of number of successful out-
comes of NSTE ACS in Registry 2 was affected by more active
of LMWH enoxaparin usage. Every percentage of reduction of
serious adverse effects costs extra USD 4.03 but it leads to
increase in the quality of health care and decrease in expendi-
tures on ill effects after discharge from the hospital.
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VKA TREATMENT RELATED COSTS IN FRANCE IN PATIENTS
WITH CHRONIC NONVALVULAR ATRIAL FIBRILLATION:
COST DATA FROM THE INTERNATIONAL STUDY OF
ANTICOAGULATION MANAGEMENT (ISAM)
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OBJECTIVES: Vitamin K antagonists (VKAs) have a narrow
therapeutic window and numerous drug and food interactions
and therefore require frequent INR monitoring. This study
aimed to estimate VKA treatment related costs in patients with
chronic nonvalvular atrial ﬁbrillation (NVAF). METHODS:
Data were collected as part of the French arm of ISAM, an Inter-
national Study of Anticoagulation Management. Cost analysis
was from a societal perspective and limited to direct medical
costs. A randomly selected sample of general practitioners (GPs)
and cardiologists (40 GPs, 19 cardiologists) established a regis-
ter of all patients who had received at least 60 consecutive days
of VKA treatment for chronic NVAF in the preceding year. Study
data were obtained from the medical record and by patient 
interview. VKA treatment related costs included INR tests, 
blood sample draws, physician consultations, nurse cost and
VKA related investigations and hospitalisations. Drug costs were
not considered. RESULTS: Of 535 eligible patients, 278 (52%)
were interviewed. A total of 3349 INR tests were collected over
a cumulative follow-up time of 259 years. The mean cost for
INR tests was 69.82€/patient/year; 40.4% of blood samples were
taken at the patient’s home by a nurse, with a mean driving dis-
tance of 4.8km, representing an additional cost of 6.37€ for each
INR taken at home (average 33.25€/patient/year). VKA treat-
ment generated 697 GP and 187 cardiologist face-to-face con-
sultations, at a cost of 70.43€/patient/year. Of 79 hospitalisations
reported during the study period, 14 were judged attributable to
VKAs by an event adjudication committee. These hospitalisa-
tions added a further 153.99€/patient/year. CONCLUSIONS:
The annual cost of ambulatory VKA follow-up was 175€ per
patient. VKA related hospitalisations in this patient sample
added 153.99€, but the exclusion of patients unable to be inter-
viewed may have resulted in underestimation of costs associated
with severe adverse events (stroke, death).
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A SHORT-TERM RETROSPECTIVE ECONOMIC EVALUATION
FOR THE TREATMENT OF MILD TO MODERATE ESSENTIAL
HYPERTENSION WITH ANGIOTENSIN II-ANTAGONISTS 
IN SPAIN
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OBJECTIVES: To perform a retrospective economic evaluation
of an 8-week clinical trial, comparing the efﬁcacy of ﬁxed daily
doses of olmesartan (20mg) versus losartan (50mg), valsartan
(80mg) and irbesartan (150mg) in patients with mild to moder-
ate essential hypertension in Spain. METHODS: A cost-
effectiveness analysis (CEA) was carried out using 2004 drug
acquisition costs for ARA-II evaluated, and proportion of
patients with controlled blood pressure (BP; diastolic BP 
< 90mmHg or a reduction from baseline ≥ 10mmHg) at week
8 as the effectiveness measurement. RESULTS: In this sort-term
study a signiﬁcantly higher reduction of DBP was achieved 
with olmesartan (-11.5mmHg, n = 145) than with losartan 
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(-8.2mmHg, n = 146), valsartan (-7.9mmHg, n = 142) and irbe-
sartan (-9.9mmHg, n = 145), p < 0.05 in each comparison. The
proportion of patients with controlled BP were 56.0% (95%
conﬁdence intervals; 47.4%–64.1%), 41.7% (33.7%–50.2%),
32.6% (24.8%–40.8%), and 52.1% (44.0%–60.8%), with
olmesartan, losartan, valsartan and irbesartan respectively at
week 8 (p < 0.05 olmesartan vs losartan and valsartan). Mean
costs were the same for all options considered, yielding olme-
sartan as the dominant option with a cost per successfully treated
patient lower (92.43€ (88.2€–96.6€)) than with the other drugs;
124.12€ (120.0 €–128.3€), 158.77€ (154.8€–162.8€) and 99.35€
(95.1€–103.6€), for losartan, valsartan and irbesartan, respec-
tively. CONCLUSIONS: Olmesartan showed a more favourable
pharmaco-economic proﬁle than losartan and valsartan in the
short-term treatment of mild to moderate essential hypertension
in Spain. Irbesartan was not statistically inferior than olmesar-
tan. Long-term studies are needed to conﬁrm these ﬁndings.
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SCREENING FOR ABDOMINAL AORTIC ANEURYSM IN MEN.
AN ECONOMIC EVALUATION BASED ON A SYSTEMATIC
REVIEW OF THE LITERATURE
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OBJECTIVES: Abdominal aortic aneurysm (AAA) is a common
disease, particularly among elderly men. Rupture of AAA is asso-
ciated with high mortality, causing about 1% of all fatalities in
men over 60 years of age. Most patients with ruptured AAA die
before they come to surgery and the overall mortality is about
80%, compared to a reported mortality during elective surgery
of 0–9%. Early detection by screening has therefore been advo-
cated and the objective of this study was to evaluate the long-
term cost-effectiveness of different screening strategies for AAA.
METHODS: A Markov cohort simulation model was developed
and different screening strategies in terms of age and risk pro-
ﬁles of the screened population and re-screening were analysed.
Assumptions and variables in the model were based on a sys-
tematic review of the literature. The cost per life year gained was
used as main outcome measure. RESULTS: The cost per life year
gained for the different screening strategies ranged from $8309
to $14,084 and was estimated to $10,474 when 65-year-old men
were screened once. Sensitivity analyses showed that the results
were robust. Variations of risk of rupture among screened and
non-screened and long-term survival affected the cost-effective-
ness substantially. The cost-effectiveness was rather insensitive to
variations in cost of screening, cost of surgery and attendance
rate. CONCLUSIONS: Screening for AAA may be cost-effective
in 65-year-old men, while screening younger men with a re-
screening could be equally cost-effective with the advantage of
more life years gained. Some aspects need to be characterized in
further detail, particularly quality of life effects related to screen-
ing for AAA, age-speciﬁc natural course of AAA and age-speciﬁc
long term survival.
PCV47
DECISION ANALYSIS ON EFFECTIVENESS AND COST-
EFFECTIVENESS OF DISEASE MANAGEMENT PROGRAMS
FOR THE TREATMENT OF HEART FAILURE
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OBJECTIVES: Congestive heart failure (CHF) is the leading
cause for hospitalization in the elderly. In a meta-analysis of 
16 randomized controlled trials (RCT) investigating disease
management programs (DMP) in the treatment of CHF, we 
previously demonstrated a statistically signiﬁcant reduction 
in mortality and rehospitalization, but cost-effectiveness of 
DMPs remains uncertain. Therefore, we sought to evaluate life
expectancy and life long medical costs for DMPs. METHODS:
Design: Cost and cost-effectiveness analysis using a 6 state
Markov Model representing the number of prior hospitalizations
(h = 1 to h = 4+) and death. Data sources: Pooled efﬁcacy data
from our meta-analyses of RCTs, SOLVD registry data for age-
dependent hospitalizations and mortality rates adjusted for 
additional beneﬁt from beta-blocker therapy and reimbursement
costs in the Australian health care system. Target population:
Patients that have been admitted with CHF. Time horizon: life-
time. Perspective: societal. Intervention: conventional therapy
and DMP. Outcome measures: Life years gained (LYG) and life-
long direct medical costs. RESULTS: For a population aged 73
at onset of CHF (27% female, 33% on beta-blocker), our model
yielded, on average, a remaining life expectancy of 3.24 years
for conventional therapy and 3.38 years for DMP. Mean undis-
counted lifetime costs per patient were estimated at 11,600€
and 12,700€ respectively. The discounted incremental cost-
effectiveness ratio (ICER) of DMP vs. conventional care was
8813€ per LYG. Assuming the beneﬁt due to DMP lasting for 5
years after the end of the actual intervention would lead to addi-
tional 5 life-months and reduce ICER to 4021€/LYG. CON-
CLUSIONS: Based on our decision analysis, DMPs prolong life,
but increase life-time costs. A cost-saving effect of DMPs as sug-
gested in some original studies could not be conﬁrmed. However,
even under conservative assumptions regarding the duration of
DMP, these programs are cost-effective when compared to other
well-accepted medical interventions in heart disease.
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ARIAL FIBRILLATION HISTORY AND ATRIOVENTRICULAR
BLOCK APPEARANCE IN PATIENTS WITH SINUS NODE
DISEASE AND SINGLE CHAMBER ATRIAL PACEMAKER—
IMPACT ON COST OF THERAPY
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OBJECTIVES: Sinus Node Disease (SND) is a common indica-
tion for implantation of a permanent pacemaker. In case of 
subsequent development of atrioventricular block (AVB) it is nec-
essary to upgrade atrial pacemaker (AAI) to dual-chamber
(DDD). The aim of the study was to evaluate the inﬂuence of
atrial ﬁbrillation (AF) history on the risk of AVB development in
patients with SND and permanent AAI and its impact on pacing
therapy costs. METHODS: Data of 752 patients with SND who
had AAI implanted between 1993 and 1997 were identiﬁed. The
history of AF was established on the basis of preoperative exam.
The records of patients were examined to ﬁnd cases that required
further procedure to upgrade AAI to DDD. The cost analysis was
performed to assess the strategy of primary DDD implantation
in those patients with SND that would receive AAI as a stan-
dard. The costs taken into consideration were: pacemaker, leads,
implantation procedure, hospitalization. The analysis of sensi-
tivity for main partial costs was performed, future costs were 
discounted. RESULTS: In the whole group of 752pts–144pts
(19.1%) required the upgrade procedure. A total of 417pts
(55.5%) had a history of AF. A total of 105pts had the subse-
quent DDD pacemaker implanted in the AF group (25.2%) and
39 in the group with no AF history (11.6%). There were savings
of 82€ per patient, in the primary AAI implantation arm, in the
whole group and 190€ Euro in the no-AF group whereas both
strategies were equal in the group with AF history. CONCLU-
